US FDA Vs. USP: Regulator Sees Biologic Product Monographs As Barrier To Biosimilars
Executive Summary
USP's proposed change aimed at harmonizing with FDA's suffix-based naming system for biologics would 'aggravate existing concerns' that biologic product-specific monographs are too inflexible and may impede development of biosimilars, agency says in a letter publicized through a tweet by the commissioner.
You may also be interested in...
USP Rivalry With US FDA Over Compendial Standards Provision Busts Into Open Legislative Fight
In a letter to Senate HELP Committee chairman Sen. Lamar Alexander and ranking member Sen. Patty Murray, USP and other stakeholders are calling for the removal of language that would exclude biological products from requirements to follow USP quality standards.
US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.
US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.